TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and Female subjects 18 years of age and older~2. Have a primary diagnosis, or a high clinical suspicion, of cancer in the lung warranting surgery based on CT/PET or other imaging~3. Are scheduled to undergo surgical thoracoscopy for diagnostic wedge resection followed by anatomic lung resection~4. Female subjects of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion~5. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments~Exclusion Criteria:~1. Previous exposure to OTL38~2. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject~3. History of anaphylactic reactions to folate, including synthetic folic acid (pteroylmonoglutamic acid) and contrast agents containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.~4. History of allergy to any of the components of OTL38, including folic acid~5. A positive serum pregnancy test at Screening or a positive urine pregnancy test on the day of surgery or day of admission for female subjects of childbearing potential~6. Clinically significant abnormalities on electrocardiogram (ECG) at screening.~7. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol and follow-up schedule~8. Impaired renal function defined as eGFR\< 50 mL/min/1.73m2~9. Impaired liver function defined as values \> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>2x ULN for total bilirubin except in subjects with Gilbert's syndrome.~10. Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to the administration of study drug~11. Known sensitivity to fluorescent light

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Near-Infrared Imaging group (Type: EXPERIMENTAL): All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
- No Imaging Group (Type: OTHER): All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bergen Psychosis Project 2 - The Best Intro Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~A:The observational cohort~* Patients 16 years old or older~* Active psychosis as determined by a score of 4 or more on one or more of the items Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).~* Or ICD-10 diagnosis corresponding to psychotic disorders or other mental disorders with psychotic features (F10-F19: .5 (psychotic disorder); F20-F29, F30.2, F31.2, F31.5, F32.3, F33.3). From which eligible patients are recruited to the B:The pragmatic, randomized, controlled trial (The Best Intro Study)~* Patients 18 years and older~* Schizophrenia spectrum and delusional disorder~* Symptoms of psychosis as determined by a score of 4 or more on one or more of the items Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).~Exclusion Criteria:~* Inability to understand spoken Norwegian.~* Patients with organic psychosis due to limbic encephalitis detected by antibodies in serum obtains at inclusion (such as NMDAR, VGKC and paraneoplastic antibodies performed at the Neuroimmunology Laboratory, Department of Neurology, Haukeland University Hospital) Pregnant or breast feeding women.~* Aripiprazole: Hypersensitivity to the active substance or to any of the excipients~* Amisulpride: Hypersensitivity to the active ingredient or to other ingredients of the medicinal product; concomitant prolactin-dependent tumours e.g. pituitary gland prolactinomas and breast cancer; phaeochromocytoma; lactation, combination with the following medications which could induce torsade de pointes: Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide. Class III antiarrhythmic agents such as amiodarone, sotalol. Other medications such as bepridil, cisapride, sultopride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin. Combinations with levodopa.~* Olanzapine: Hypersensitivity to the active substance or to any of the excipients. Patients with known risk of narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amisulpride (Type: ACTIVE_COMPARATOR): None
- Aripiprazole (Type: ACTIVE_COMPARATOR): None
- Olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A single new focal unilateral stroke with diagnosis verified by brain imaging (MRI) or CT scan that has occurred at least 6 months prior to enrollment.~* Age 18 years of age and older.~* Upper extremity Fugl-Meyer score \>=7 or \<=38 (max 66). (These thresholds include neither hemiplegic nor fully recovered motor function in 14 muscles of the shoulder, elbow, and wrist.)~* Cognitive function sufficient to understand the experiments and follow instructions (Mini-Mental Status Score of 22 and higher or interview for aphasic subjects).~* Willingness to avoid any new alternative arm rehabilitative approaches for the duration of the study.~* Written informed consent to participate in the study.~Exclusion Criteria:~* A fixed contracture in the affected limb that prevents movement along the entire dynamic range required by either robot-assisted or intensive comparison therapy.~* Joint pain that occurs within the range of motion required by the intervention protocols (intensive comparison therapy and robot-assisted therapy).~* Enrolled in or planning to enroll in another interventional research trial that involves the upper limbs using procedures proposed to enhance or limit the function of the upper extremity (such as adjuvant rehabilitation or Botox injections) during the 36 weeks of participation.~* Prior experience with robot-assisted therapy or intensive comparison therapy for the upper limb as described in this specific study.~* A complicating medical condition that would prevent completion of the trial.~* Unable to complete the nine-month study, e.g., extended planned vacation.~* Any other known pre-existing bone diseases that might increase the risk of bone fracture or other injury from intensive comparison therapy or robot-assisted therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Robot-Assisted Therapy - MIT-MANUS System
- Arm 2 (Type: ACTIVE_COMPARATOR): Intensive Comparison Therapy
- Arm 3 (Type: OTHER): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented postprandial hypoglycaemia (\<3.9 mmol/l) by 6-day CGM or during a MMT~* Documented plasma glucose concentration excursions \>5.0 mmol/l by 6-day CGM or a MMT~* Haemoglobin levels for women \>7.3 mmol/l and for men \>8.3 mmol/l~* Ferritin \>10 μg/l~* Cobalamin \>150 pmol/l~* Fasting plasma glucose concentration within the range of 4.0-6.0 mmol/l CKN-DASI-RYGB protocol version 1.0 6~* Normal electrocardiogram (ECG)~* Negative urine human chorionic gonadotropin (hCG) (for fertile women)~Exclusion Criteria:~* Treatment with medication(s) affecting insulin secretion or any antidiabetic drugs~* Treatment with antipsychotics~* Current participation in another clinical trial with administration of investigational drug.~* Previous exposure to dasiglucagon (otherwise known as ZP4207)~* History of liver disease that is expected to interfere with the anti-hypoglycaemic action of glucagon (e.g. liver failure or cirrhosis).~* Pregnancy~* Breastfeeding~* Any factors that, in the opinion of the site principal investigator or clinical protocol chair, would interfere with the safe completion of the study, including medical conditions that may require hospitalization during the trial or allergy to the ingredients in the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 80 ug of sc dasiglucagon (Type: EXPERIMENTAL): 80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
- 200 ug of sc dasiglucagon (Type: EXPERIMENTAL): 200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
- 0.4 mL of sc saline (placebo) (Type: PLACEBO_COMPARATOR): 0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intrauterine Lidocaine Infusion and Oral Tramadol on Pain During Diagnostic Office Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Menopausal patients with an indication for office hysteroscopy (postmenopausal bleeding or abnormal ultrasound findings)~* Consent to the procedure~Exclusion Criteria:~* Positive Chlamydia culture.~* patients who have an Allergy to local anesthesia or tramadol.~* A previous adverse reaction to any of the drugs used in the study.~* Patients were receiving any form of analgesia or current use of monoamine oxidase inhibitors.~* Nulliparous patients and patients with cervical pathology, retroverted uterus (detected by transvaginal ultrasound), and previous cervical surgery.~* Patients who have severe vaginal bleeding.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lidocaine infusion arm (Type: EXPERIMENTAL): The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
- tramadol arm (Type: ACTIVE_COMPARATOR): will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
- placebo group (Type: PLACEBO_COMPARATOR): will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adenocarcinoma of gastric-esophagal junction~* stage II to III~* unidimensional measurable disease~Exclusion Criteria:~* surgery of primary tumor~* metastasis~* prior chemo- or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- one arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: China Micra Transcatheter Pacing Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC/AHA/HRS 2008 guidelines and China guideline.~2. Subjects who are willing to participate in study through consent and willing to undergo study specific required procedures with expectancy of geographically stable for follow up duration.~3. Subjects who are at least 18 years of age.~Exclusion Criteria:~1. Subject has an existing or prior pacemaker, ICD or CRT device implant.~2. Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment.~3. Subjects with current implantation of neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed.~4. Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD).~5. Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.5 cm) could not be obtained with programmer head.~6. Subjects whose femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter.~7. Subjects who are considered as unable to tolerate an urgent sternotomy.~8. Subjects with a known intolerance to Nickel-Titanium (Nitinol) Alloy.~9. Subjects for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated.~10. Subjects with a life expectancy of less than 12-months.~11. Subjects who are currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when document pre-approval is obtained from the Medtronic study manager.~12. Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence.~13. Subjects with exclusion criteria required by local law (age or other).~14. Subjects with medical condition which precludes patient from participation in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micra Implant Group (Type: EXPERIMENTAL): Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Menopausal Sleep Fragmentation and Body Fat Gain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy premenopausal women 18-45 years old~* Regular sleep schedule~* Limited alcohol and caffeine intake~* Regular monthly menstrual cycles~* No lifetime history of hot flashes~* Willingness to use approved methods of contraception during study~* Not obese~* Good general health~Exclusion Criteria:~* Contraindication, hypersensitivity or previous adverse reaction to gonadotropin releasing hormone agonists~* Pregnancy~* Breastfeeding~* Tobacco use~* Contraindicated systemic hormone medications or centrally active medications~* Shift workers or recent/expected time zone travel~* Obstructive sleep apnea~* Insomnia symptoms~* Diagnosis of osteoporosis or osteopenia~* Hypothalamic-pituitary-adrenal axis disorders~* Diabetes~* Gastric bypass, metabolic disorders, or other related conditions~* Abnormalities on screening laboratory tests~* Substantial hearing impairment~* Cardiovascular illness~* Neurological illness~* Recent psychiatric illness or substance-use disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Study arm (Type: EXPERIMENTAL): Participants completed 2 nights of unfragmented sleep followed by 3 nights of experimentally-fragmented sleep during high estradiol (E2) phase of their menstrual cycle (Sleep Block 1). A subset of participants repeated these procedures in an experimentally-induced low-E2 state (Sleep Block 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. aged greater than 20 years who have persistent H. pylori infection after two treatments and are willing to receive third line rescue regimens.~Exclusion Criteria:~1. children and teenagers aged less than 20 years,~2. history of gastrectomy,~3. gastric malignancy, including adenocarcinoma and lymphoma,~4. previous allergic reaction to antibiotics (Amolin, Klaricid, Cravit) and prompt pump inhibitors (esomeprazole),~5. contraindication to treatment drugs,~6. pregnant or lactating women,~7. severe concurrent disease.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sequential, susceptibility guided (Type: EXPERIMENTAL): single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Subjects with Philadelphia chromosome positive (Ph+) (or BCR/ABL+) chronic phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate.~* Men and women, 18 years or older~* Adequate hepatic function~* Adequate renal function~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized.~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Subjects who are eligible and willing to undergo transplantation during the screening period~* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy~* Uncontrolled or significant cardiovascular disease~* Medications that increase bleeding risk~* Medications that change heart rhythms~* Dementia or altered mental status that would prohibit the understanding or rendering of informed consent~* History of significant bleeding disorder unrelated to CML~* Concurrent incurable malignancy other than CML~* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete